focus -WSS

focus

author：focus 2025-10-01 23:43:28 - browse：8445

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Color Health wants to make cancer screenings convenient

explore

WSS

Change Healthcare cyberattack shows risk of industry consolidation

Doctor of U.S. President Joe Biden says he is fit for duty

Anesthesiologist group: stop taking Ozempic before surgery

Are embryos people? Reproductive medicine's future depends on the answer

Doctor of U.S. President Joe Biden says he is fit for duty

Virginia high school admissions case could be legal follow

entertainment

focus

entertainment

What does generative AI mean for health care? We asked experts

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

State Dept. review finds Biden bears some blame for Afghanistan failures

Moonlake's readout produced a cash windfall. Risks remain

Medicare details structure of new drug price negotiation program

Walensky prepares to leave CDC — and Congress — behind

What does generative AI mean for health care? We asked experts

Bright Health sells Medicare Advantage business to Molina

At least 13 dead in Texas as scorching temps continue

Using force crossed my mind when examining a defiant young patient

focus

How one medical school became remarkably diverse

Using force crossed my mind when examining a defiant young patient

At least 13 dead in Texas as scorching temps continue

Study fuels hope CAR

Cancer drug shortages should be causing more outrage

Walensky prepares to leave CDC — and Congress — behind

explore

focus

hotspot

hotspot